Introduction
RS, cancer, tumor, tumors
TUMOR, INFILTRATION, METASTASIS, CANCER, SOLID TUMORS, TUMORS, COMPLICATIONS
Immune-checkpoint inhibitor immunotherapy and stereotactic body radiotherapy (SBRT) are powerful stand-alone cancer therapies and mechanistic studies support combination regimens (Historically, SBRT for large tumors, tumors measuring more than 5 cm or more than 65 cc, was considered neither safe nor feasible due to nearby critical organs at risk (OARs) and/or radiation dose tolerance, which is based on the probability of normal tissue complications (We previously demonstrated that the combination of multi-site SBRT+P (There is a paucity of clinically useful biomarkers to identify patients that may benefit from combined SBRT and immunotherapy. In our initial reported cohort, we investigated several clinical and molecular biomarkers and found that response of the irradiated metastasis (Noninvasive means to evaluate immune infiltration of tumors and predict response are also of interest. A validated CD8Circulating cytokines, notably IL-8, have also been associated with outcome to PD1/L1 checkpoint blockade (Here, we describe the safety and preliminary efficacy of SBRT+P in a dedicated cohort of patients with advanced solid tumors with the incorporation of an expansion cohort of patients with large, partially irradiated tumors. We explore partial-Rx and complete-Rx tumor control, the implications of tumor response, RS, and whether cytokines associated with innate and adaptive immune pathways can be prognostic for clinical outcomes (